Search results
AstraZeneca completes Amolyt Pharma acquisition
Pharmaceutical Technology· 35 minutes agoEneboparatide is in Phase III development for hypoparathyroidism and binds to the parathyroid hormone (PTH) receptor with high affinity....
Eneboparatide is in Phase III development for hypoparathyroidism and binds to the parathyroid hormone (PTH) receptor with high affinity....